CN1947719A - Application of aspirin for preventing and treating osteoporosis - Google Patents
Application of aspirin for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN1947719A CN1947719A CN 200610143026 CN200610143026A CN1947719A CN 1947719 A CN1947719 A CN 1947719A CN 200610143026 CN200610143026 CN 200610143026 CN 200610143026 A CN200610143026 A CN 200610143026A CN 1947719 A CN1947719 A CN 1947719A
- Authority
- CN
- China
- Prior art keywords
- bone
- aspirin
- cyclophosphamide
- group
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of aspirin in preparing the medicines in the form of pill, tablet, particle, capsule, injection, etc for preventing and treating osteoporosis is disclosed.
Description
The technical field osteoporosis be one worldwide, more and more cause the health problem that people pay attention to.About 200,000,000 people in the whole world suffer from osteoporosis at present, and its sickness rate has leapt to commonly encountered diseases, frequently-occurring disease the 7th.Estimate that ill total number of persons surpasses 200,000,000.Osteoporosis is the modal disease of old people.The present invention relates to the application of aspirin in protect against osteoporosis.Aspirin be clinical commonly used a kind of have analgesic, analgesia and anti-inflammatory drug.In the treatment rheumatism, diseases such as rheumatoid disease have tangible curative effect, this seminar discovers that aspirin has prevention and therapeutical effect preferably to osteoporosis, and to adrenal gland's glucocorticoid, drug induced osteoporosis such as cyclophosphamide also has and has prevention and therapeutical effect preferably.
The background technology osteoporosis be one worldwide, more and more cause the health problem that people pay attention to.About 200,000,000 people in the whole world suffer from osteoporosis at present, and its sickness rate has leapt to commonly encountered diseases, frequently-occurring disease the 7th.Estimate that ill total number of persons surpasses 200,000,000.Osteoporosis is the modal disease of old people.In the U.S. and western countries, in the age surpasses 55 years old postclimacteric women, there is the people of half to suffer from the different osteoporosis of degree, and in the old people of over-65s, suffers from osteoporosis person up to more than 95%.Along with the reach of science and human progress, the average life span constantly prolongs, and aging population increase sharply, and osteoporotic sickness rate is also along with increase rapidly occurring.Estimate to the year two thousand fifty whole world over-65s the old people will be increased to 15.55 hundred million by present 3.23 hundred million, osteoporosis causes hip fracture generation number also will be increased to 6,260,000 by present 1,660,000 when the time comes, and wherein the patient of Asia, Latin America, the Middle East and African country will account for more than 70%.According to official statistics, the U.S. is used for directly and indirectly costing of osteoporosis aspect every year and reaches 10,000,000,000 dollars; The fund that the health of Britain and social security institution every year provide for osteoporosis is above 500,000,000 pounds; France only pays the patient's of 30,000 fracture of femoral neck about 13.5 hundred million French Francs of hospitalization cost every year on average.Huge social like this and financial burden that osteoporosis caused have constituted a serious global problem, have caused the very big concern of countries in the world.The arrival of aging society is increased osteoporotic incidence rate day by day, serious threat people's quality of life.WHO is defined as 2000-2010 " osteoarthritis 10 years ".
China is the maximum country of world population, wherein aging population account for the Asia aging population 1/2 and world population 1/5.The osteoporosis Epidemiological study result in Beijing, Shanghai and 3 cities, Chengdu shows, 60-69 year osteoporotic incidence rate women of age bracket and male are respectively about 60% and 30%.China's large population base, sufferers of osteoporosis face have reached 6,000 ten thousand～8,000 ten thousand examples, and this brings serious burden [2] for family and society.People according to another statistics national over-65s in 2000 has 1.3 hundred million, accounts for 10.7% of national population, has become typical veteran form country.And the patient who suffers from osteoporosis accounts for 90% in these crowds, and the patient of hip fracture will have 12%～40% to die from various complication in 1 year.50% human action inconvenience is also arranged in the survivor.This has not only caused serious body and mind to wreck to patient, has increased huge manpower and financial resources burden also for simultaneously family and society.Therefore, preventing and treating osteoporosis is defying age, life-saving, the very urgent research topic of the assurance people's quality of life.
At present both at home and abroad the protect against osteoporosis medicine is very limited, and bone mineralising promoter commonly used is limited as calcium preparation, vitamin D curative effect; Though bone resorption inhibitor such as estrogen, calcitonin, diphosphate, ipriflavone etc. have certain effect, untoward reaction is also many, influences clinical practice, and the curative effect of bone formation-promoter such as fluoride is disputed on always, and the U.S. is also not listing [2-5] so far.Aspect clinical treatment, from controversies in hormone replacement in the elderly, to the diphosphonic acid salt, the control of medicines such as the calcitonin several important development phases of having passed by, just changing at present treatment research over to cytokines such as bone morphogenic protein-2 Pseudobulbus Bletillae (Rhizoma Bletillae) interleukin, but, to so far, these are used to prevent and treat osteoporotic medicine, and many side effect are all arranged, and some curative effect is general, some costs an arm and a leg, at present still do not have a kind of generally acknowledged ideal medicament, therefore, the searching high-efficiency low-toxicity is prevented and treated osteoporotic medicine and is remained the urgent task of pharmacology worker.
Aspirin is clinical medicine commonly used, the history of coming out existing more than 100 year, and it is analgesic, analgesia, antiinflammatory action is widely applied clinically to prove widely.This project team finds that aspirin has prevention and treats osteoporotic effect, can be used for preventing and treating osteoporosis in the research of seeking osteoporosis.
Summary of the invention: aspirin can be used for prevention and treatment osteoporosis.
The specific embodiment: have prevention and treat osteoporotic effect in order to prove aspirin, we cause osteoporosis and the immunosuppressant model of rat as tool drug with cyclophosphamide, the action effect of the aspirin of low dosage in the observation, and compare with positive control medicine calcium carbonate dimension D, now report as follows:
1 materials and methods
1.1 medicine and reagent
1.1.1 medicine aspirin (medicinal raw material medicine): provide by Shandong XinHua Pharmacy stock Co., Ltd, adjust to the laboratory desired concn with the short molten back of small amount of ethanol with normal saline during use.Middle dosage is to be converted by normal adult 500mg consumption per day according to the bulk area method, and diluting 5 times is low dosage.Cyclophosphamide: Hengrui Medicine Co., Ltd., Jiangsu Prov., lot number: 403501.Calcium carbonate dimension D sheet: U.S. ounce drugmaker, lot number: 5B16656, every is equivalent to calcium 300mg, VitD100 unit.
1.1.2 reagent hydrochloric acid tetracycline: new Asia, Shanghai pharmaceutical factory produces, lot number: 891224-18; Methyl methacrylate: the Beijing Chemical Plant produces, lot number: 940117; Calcein (Sigma chemical Co.USA, lot:61F0527); Osseous tissue dyestuff (Masson-Goldner Trichrome; Poncean Fuchsin Stock; Phosotungstic acid-Oragne; Light green; Sliver Nitrate) etc. be the Sigma product.
1.2 experimental apparatus AE240 electronic balance (prunus mume (sieb.) sieb.et zucc. Teller-Shanghai branch company of Tuo benefit instrument company produces), XSZ-0800 biological microscope (Wuzhou City Optic Instrument Factory, Guangxi), blood cell counting plate (Shanghai refinement biochemical instrument company limited), low speed saw (BuehlerLTD USA), Leica histotome (Germany), the semi-automatic image analyzer of LEICA QWN (German Lycra).
1.3 experimental technique
1.3.1 laboratory animal and 45 of 3 months old rats of grouping, male and female half and half, body weight (207.23 ± 42.2) g is provided by Guangdong Medical College's Experimental Animal Center, SPF level, the animal quality certification number: 2005A023.Be divided into 5 groups immediately by the body weight principle of reciprocity, 9 every group.A group is the normal control group: this group rat is irritated stomach and give 5mlkg-1d-1 normal saline every day.B group is model group (cyclophosphamide group), and this group rat is irritated stomach and give cyclophosphamide 4.5mgkg-1d-1 every day.C organizes positive medicine matched group (calcium carbonate dimension D group), and this group rat irritates that stomach gives cyclophosphamide 4.5mgkg-1d-1 and calcium carbonate is tieed up D0.4mgkg-1d-1 every day.D group is middle dosage aspirin group: this group rat is irritated stomach and give cyclophosphamide 4.5mgkg-1d-1 and aspirin 45mgkg-1d-1 every day.E group is low dosage aspirin group: this group rat is irritated stomach and give cyclophosphamide 4.5mgkg-1d-1 and aspirin 9mgkg-1d-1 every day.5 treated animals are all freely drunk water and are taken food standard feed.Experiment is total to administration 15 days, and when experiment finished, the tail vein was got blood and done numeration of leukocyte.Back heart extracting blood is put to death, and gets thymus and spleen AE240 scales/electronic balance weighing, calculates the organ index, and index and spleen index refers to the ratio of spleen weight and body weight, and thymus index refers to the ratio of thymic weight and body weight.Get the left side tibia and carry out the measurement of osseous tissue morphometry.
1.3.2 the osseous tissue morphometry measure [12] rat before execution 11,10d and 4,3d give tetracycline (30mgkg-1) and calcein (8mgkg-1) labelling respectively each 2 times, to form pair fluorescent labelinies at osseous tissue.Measure body weight behind the rat administration 15d, put to death and get the left side tibia, eliminate muscle and tissue, with the low speed saw it is divided into 2 sections, get epimere and expose medullary cavity to the open air, be fixed in 10%PBS formalin solution 24h, by sclerous tissues's Sectioning methyl methacrylate embedding undecalcified bone, cut two 4 μ m thin slices and one 9 μ m sheet, thin slice carries out Masson-Coldner dyeing and AgNO3 dyeing back mounting respectively, thick osteocomma is direct mounting then, and thick, thin slice all carries out the bone morphometry parameter measurement of spongy bone to the far-end 3mm scope at distance epiphyseal line 1mm place.Osseous tissue morphometry static parameter comprises: bone trabecula area percent (%Tb.Ar), bone trabecula thickness (Tb.Th), bone trabecula quantity (Tb.N), the little fine strain of millet separating degree of bone (Tb.SP), dynamic parameter comprise fluorized marking girth percent (%L.Pm), mineralising deposition (MAR), the little fine strain of millet girth of bone formation rate (BFR/BS), the little fine strain of millet area of bone formation rate (BFR/BV), the little fine strain of millet volume of bone formation rate (BFR/TV), every millimeter amount of osteoclast (Oc.N/mm).
1.3.4 the date processing parameter value is with (X ± S) represent, the diversity between each group is checked with t between group.Represent the variation (as: rate of change A=(to be compared group/A group-1) * 100%) of each experimental group rat relative parameter with rate of change
2 results
2.1 aspirin is to the influence of cyclophosphamide rat body weight, organ index and blood leukocytes
Aspirin sees Table 1 to the influence of cyclophosphamide rat body weight, organ index and blood leukocytes:
Table 1 aspirin is to the influence of cyclophosphamide rat body weight, organ index and blood leukocytes
| Group | Body weight (g) | Index and spleen index (mg/g) | Thymus index (mg/g) | Blood leukocytes number (109/L) |
| The low amount of amount aspirin group rate of change A (%) rate of change B (%) E aspirin group rate of change A (%) rate of change B (%) among A Normal group B endoxan group rate of change A (%) C calcium carbonate dimension D group rate of change A (%) rate of change B (%) D | 290.2±52.4 277.0±60.1 -4.55 283.9±53.6 -2.17 2.49 264.7±53.7 -8.79 -4.44 270.6±54.2 -6.75 -2.31 | 3.44±1.27 2.23±0.81 -35.2 * 2.70±1.20 -21.5 21.1 2.90±1.03 -15.7 30.0 2.58±1.42 -25.0 15.7 | 1.23±0.40 1.44±0.43 17.1 1.32±0.41 7.32 -8.33 1.33±0.60 8.13 -7.64 1.15±0.28 -6.50 -20.1 | 26.0±7.79 13.1±5.93 -49.6 *** 12.7±5.61 -51.2 *** -3.05 14.3±8.06 -45.0 ** 9.16 13.2±5.39 -49.2 *** 0.76 |
Annotate: n=9; A, B are that rate of change: A compares with matched group, and B compares with the cyclophosphamide model group;
P＜0.05，
**P＜0.01，
***P＜0.001
By table 1 as seen, cyclophosphamide illustrates that to body weight and the not obviously influence of thymus index of rat the cyclophosphamide of this test dose is little to rat toxicity.But index and spleen index (p＜0.05) and blood leukocytes number (p＜0.001) all have obvious decline, and the prompting cyclophosphamide can produce tangible immunosuppressive action to rat at this experiment consumption.And the immunosuppressant that aspirin and calcium carbonate dimension D can not resist cyclophosphamide.
2.2 aspirin is to the morphologic influence of cyclophosphamide rat tibia osseous tissue
The animal bone girder that rats in normal control group tibial bone tectology is observed visible this group presents that structure is tight, even thickness, seriality are good; Visible this treated animal trabecular bone structure of cyclophosphamide model group rat tibia osseous tissue morphological observation is obviously sparse, tiny, is tuberosity or button-type individually, large stretch of no bone trabecula bone marrow district occurs; The trabecular bone of visible this treated animal of calcium carbonate dimension D group rat tibia osseous tissue morphological observation obviously increases slightly than the cyclophosphamide model group, increases, and seriality is recovered to some extent; The bone trabecula even thickness of visible this treated animal of middle dosage aspirin group rat tibia osseous tissue morphological observation is evenly distributed, and seriality is good, has all had significantly in quantity, width, length and the distribution of trabecular bone than the cyclophosphamide model group and has improved; The trabecular bone of visible this treated animal of low dosage aspirin group rat tibia osseous tissue morphological observation is many and thick, arrangement is orderly, and seriality is better, obviously improves than the cyclophosphamide model group.
2.3 aspirin sees Table 2 to the aspirin that influences of cyclophosphamide rat tibia osseous tissue morphometry static parameter to the influence of cyclophosphamide rat tibia osseous tissue morphometry static parameter:
Table 2 aspirin is to the influence of cyclophosphamide rat tibia osseous tissue morphometry static parameter
| Group | Bone trabecula area percent (%) | Bone trabecula thickness (μ m) | Bone trabecula quantity (mm-1) | The little fine strain of millet separating degree of bone (μ m) |
| The low amount of amount aspirin group rate of change A (%) rate of change B (%) E aspirin group rate of change A (%) among A Normal group B endoxan group rate of change A (%) C calcium carbonate dimension D group rate of change A (%) rate of change B (%) D | 11.9±4.08 6.1±2.01 -48.7 **11.1±4.27 -6.72 82.0 *13.8±4.80 16.0 126.2 ***12.0±4.63 0.84 | 51.5±6.74 42.2±6.10 -18.0 **52.1±4.91 1.16 23.4 **55.6±6.97 7.96 31.8 **53.7±5.10 4.27 | 2.33±0.8 1.45±0.4 -37.8 * 2.11±0.7 -9.44 45.5 * 2.50±0.8 7.30 72.4 ** 2.20±0.7 -5.58 | 422±143 708±247 67.8 **472±173 11.8 -33.3 *396±190 -6.16 -44.1 *446±181 5.69 |
| Rate of change B (%) | 96.7 ** | 27.2 ** | 51.7 * | -37.0 * |
Annotate: n=9; A, B are that rate of change: A compares with matched group, and B compares with the cyclophosphamide model group;
P＜0.05，
**P＜0.01，
***P＜0.001
By table 2 as seen: cyclophosphamide can make rat tibia epimere Grafting Cancellous Bone Bolt girder area percent and bone trabecula thickness significantly descend (P＜0.01), bone trabecula quantity decline 37.8% (P＜0.05), and the little fine strain of millet separating degree of bone has increased by 67.8% (P＜0.01); The prompting cyclophosphamide can make the trabecular bone of rat obviously thinning, attenuation, even fracture, and the bone marrow cavity increases.Bone trabecula quantity, thickness and the area percent of aspirin and calcium carbonate dimension D control group all significantly increase (P＜0.01), and the bone trabecula separating degree reduces (P＜0.05), in this results suggest, the aspirin of low amount and calcium carbonate dimension D can effectively resist the inductive osteoporosis sample of cyclophosphamide institute and change, increase the bone amount, make bone trabecula tight, seriality is strong.
2.4 aspirin is to the influence of cyclophosphamide rat tibia osseous tissue morphometry dynamic parameter
Aspirin sees Table 3 to the influence of cyclophosphamide rat tibia osseous tissue morphometry dynamic parameter
Table 3 aspirin is to the influence of cyclophosphamide rat tibia osseous tissue morphometry dynamic parameter
| Group | ％L.Pm/％ | MAR | BFR/BS | BFR/BV | BFR/TV | Oc.N/mm |
| The low amount of amount aspirin group rate of change A (%) rate of change B (%) E aspirin group rate of change A (%) rate of change B (%) among A Normal group B endoxan group rate of change A (%) C calcium carbonate dimension D group rate of change A (%) rate of change B (%) D | 8.49±4.1 4.18±1.0 -50.8 *12.4±8.7 46.0 196.6 *18.1±14.2 113.2 330.0 *10.4±6.7 22.5 148.8 * | 0.843±0.15 0.661±0.20 -21.6 *1.116±0.24 32.4 *68.8 ***1.288±0.28 52.8 **94.8 ***1.279±0.29 51.7 **93.5 *** | 7.22±4.2 2.81±1.2 -61.1 *14.9±10.8 106.4 430.2 **18.9±12.9 161.8 *572.6 **12.9±8.51 78.7 359.1 ** | 85.2±46 42.6±21 -50.0 * 179.3±134 110.4 320.9 * 197.3±147 131.6 * 363.1 ** 146.5±96 71.9 243.9 ** | 9.06±3.3 2.52±1.4 -72.2 ***15.4±8.9 70.0 511.1 **20.7±15.3 128.5 *721.4 **16.8±12.3 85.4 566.7 ** | 83.3±25 92.1±24 10.6 81.3±15 2.40 -11.7 68.0±18 -18.4 -26.2 71.6±17 -14.0 -22.2 |
Annotate: n=9; A, B are that rate of change: A compares with matched group, and B compares with the cyclophosphamide model group;
P＜0.05，
**P＜0.01，
***P＜0.001
By table 3 as seen, cyclophosphamide makes all obviously decline (P＜0.05) of five osteoplastic indexs of rat, the little fine strain of millet volume of bone formation rate 72.2% (P＜0.001) that descended wherein, though and every millimeter amount of osteoclast has risen 10.6%, difference nonsignificance (P＞0.05); The prompting cyclophosphamide obviously suppresses bone formation under the situation that does not influence bone resorption, make osteoblastic quantity, the active reduction, and the bone matrix mineralising reduces, and bone is built and is in the negative balance.Aspirin and calcium carbonate dimension D obviously increase the bone formation parameter value of cyclophosphamide rat, and wherein three bone formation rates all are increase substantially (P＜0.01), and the normal rat of bone mineralising deposition also has obvious rising (P＜0.01); In the prompting, the aspirin of low dosage and calcium carbonate dimension D can effectively resist the bone formation inhibitory action of cyclophosphamide, promotes osteoblastic self increment and differentiation, increases collagen mineralising and new bone formation.
3. discuss
3.1 cyclophosphamide can cause experimental rat and produce immunosuppressant, aspirin does not have preventive effect to this
Cyclophosphamide is as clinical widely used chemotherapeutics, tangible immunosuppressive action is arranged, the cyclophosphamide dosage that this experiment is adopted is to the not influence of body weight of rat, also not obviously influence of thymus index to rat, pointed out this experimental rat also not produce tangible dealed with medicine went, but the cyclophosphamide of this experiment consumption can make peripheral white blood cell of rat and index and spleen index reduce significantly, has produced tangible immunosuppressive action.And aspirin also can't resist this immunosuppressive action, can promote the generation of immune molecule, interferon and interleukin-1 with aspirin and the report result of human body immunity improving power is inconsistent, may be relevant with using dosage and mechanism of action, remain further to be studied.
Obviously lose 3.2 cyclophosphamide can cause experimental rat bone amount, the aspirin of this test dose can effectively prevent bone loss
From the static parameter result of osseous tissue morphometry research as seen: cyclophosphamide can make the rat bone amount reduce, and trabecular bone structure is loose degenerates, and the prompting cyclophosphamide can make rat produce tangible bone loss, causes typical osteoporotic morphological change; And aspirin can make bone trabecula increase, chap, increase the bone amount of cyclophosphamide rat, improve the bone microstructure, and the effect of middle dosage is better than low dosage slightly, pointed out aspirin to have the effect that the prevention cyclophosphamide causes osteoporosis rat, this effect may improve effects such as blood flow circulation and inhibition lipid over oxidation with aspirin relevant.
3.3 it is relevant with its inhibition bone formation that cyclophosphamide causes the experimental rat osteoporosis, the prevention mechanism of aspirin is to promote bone formation
Skeleton is among whole life process all is in bone resorption and osteoplastic dynamic equilibrium, and this balance and osteoclast and osteoblastic function are closely related.The osteoblast that any factor causes generates minimizing, activity suppresses or the osteoclast generation increases, overactivity, all will make bone formation be weaker than bone resorption, and cause that bone loss causes osteoporosis.
Show from the dynamic parameter result of osseous tissue morphometry research: the cyclophosphamide group can reflect osteoblast quantity and active %L.Pm/%, MAR has descended 50.8% respectively, 21.6%, represent the leading indicator BFR/BV of bone formation and bone conversion active degree to descend 50%, and bone resorption parameter Oc.N/mm does not have obvious change yet.It is under the situation that does not influence bone resorption that the prompting cyclophosphamide induces rat to produce osteoporosis, reduces osteoblastic quantity and activity, makes bone formation be weaker than bone resorption, and causes rat bone to be lost.The %L.Pm/% of aspirin group, MAR, three indexs of BFR/BV all increase substantially, and low dose group has increased by 148.8%, 95.3%, 243.9% respectively; Middle dosage group has then increased by 330%, 94.8%, 363.1% respectively, and normal rat also is significantly increased (P＜0.05); And the Oc.N/mm of two dosage groups change does not have significance, and the osteoporosis of having pointed out aspirin prevention cyclophosphamide to cause rat is owing to raise function of osteoblast, promotes bone formation, makes bone formation be better than bone resorption.
3.4 aspirin prevention cyclophosphamide causes osteoporotic mechanism and inquires into
Cyclophosphamide is to osteoplastic inhibitory action, may be because: (1) bone formation and function of osteoblast are closely related, and osteoblast originates from the Interstitial cell of polyenergic bone marrow matrix, and major function is to secrete ossein, and participate in the osteoid mineralising, promote new bone formation [14].Cyclophosphamide can destroy cell DNA and suppress nucleic acid synthetic, and Interstitial cell that may be by having suppressed bone marrow matrix is lowered into the osteocyte activity to osteoblast differentiation, the synthetic of collagen is obstructed with mineralising, thereby suppresses bone formation, causes bone loss.(2) osteocyte and immunocyte cytokine and humoral factor by respectively making a fresh start and discharging, bring into play the function associated with each other between bone marrow and the bone jointly, ensureing the bone calcium balance, supporting bone formation and bone to rebuild, in case balance is destroyed, bone formation then can be suppressed [14].Cyclophosphamide can obviously reduce bone marrow nucleated cell quantity as immunosuppressant, destroys bone marrow microenvironment, most probably by the balance of destruction bone with immunity, and suppresses bone formation.(3) cyclophosphamide damage gastrointestinal tract makes body weaken calcareous absorption and utilization, can reduce by sedimentary bone calcium, and influences the mineralising of bone.
Aspirin prevention cyclophosphamide causes osteoporotic mechanism and inquires into: (1) aspirin has osteoplastic facilitation, makes %L.Pm/%, MAR, and important bone formation index such as BFR all rises appreciably, and wherein normal rat of the bone formation of middle dosage group is active.(2) the bibliographical information aspirin has the effect of removing superoxides enzyme, hydroxyl and other free radicals, has the antioxidant activity of protection cell DNA, may resist the influence that cyclophosphamide is synthetic to osteoblast and break up, and promotes the bone formation effect.(3) aspirin has and suppresses hematoblastic gathering, alleviates the blood coagulation reaction, and the effect of microcirculation improvement, this effect can improve and bone is rebuild mutually close alternative bone marrow microcirculation environment, to the nutrition of bone with improve function of osteoblast and have great importance; (4) aspirin has the effect that promotes that high density lipoprotein forms, and this effect can suppress the over oxidation of lipid, and prevention of arterial is atherosis, can improve blood circulation in the bone simultaneously, suppress medullary cell and become fatization, thereby it is normal to keep bone metabolism.
3.5 aspirin prevention cyclophosphamide causes osteoporotic meaning
(1) use in conjunction is extensively applied to tumor treatment in the oncotherapy cyclophosphamide, and aspirin also begins to be used to developing of prophylaxis of cancer.And the two is from different perspectives to tumor cell generation effect, and wherein cyclophosphamide is to suppress its growth and breeding by direct tumoricidal DNA; Aspirin then is by effects [7] such as the expression that suppresses COX-2, promotes apoptosis of tumor, and prophylaxis of cancer takes place and shifts.The bone loss that aspirin can resist cyclophosphamide effectively and caused is observed in this research, if The combined can be applied to oncotherapy, so both can strengthen the antitumor action of cyclophosphamide, but the generation of prevention of osteoporosis again.
(2) use in conjunction is treated clinically in rheumatism, and cyclophosphamide and aspirin all have been widely used in the rheumatismal control.Cyclophosphamide can reduce inflammation and suppress immune system as immunosuppressant, and main by changing the synthetic of DNA, interference cell is bred and worked; Aspirin reduces the generation of inflammation material, a series of symptoms that control inflammation and cause by suppressing Cycloxygenase.If can The combined be applied to rheumatismal treatment, rheumatismal symptom, the bone loss that has prevented cyclophosphamide to cause have again both been controlled effectively with suitable dosage.
Claims (1)
1, aspirin is in the application of protect against osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610143026 CN1947719A (en) | 2006-10-29 | 2006-10-29 | Application of aspirin for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610143026 CN1947719A (en) | 2006-10-29 | 2006-10-29 | Application of aspirin for preventing and treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1947719A true CN1947719A (en) | 2007-04-18 |
Family
ID=38017407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610143026 Pending CN1947719A (en) | 2006-10-29 | 2006-10-29 | Application of aspirin for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1947719A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2408434A1 (en) * | 2009-03-16 | 2012-01-25 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| CN102397550A (en) * | 2011-08-30 | 2012-04-04 | 广东医学院 | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
-
2006
- 2006-10-29 CN CN 200610143026 patent/CN1947719A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2408434A1 (en) * | 2009-03-16 | 2012-01-25 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| JP2012520883A (en) * | 2009-03-16 | 2012-09-10 | アイピントゥル，エルエルシー | Treatment of Alzheimer's disease and osteoporosis and reduction of aging |
| EP2408434A4 (en) * | 2009-03-16 | 2013-11-27 | Ipintl Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| CN102397550A (en) * | 2011-08-30 | 2012-04-04 | 广东医学院 | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
| CN102397550B (en) * | 2011-08-30 | 2013-05-08 | 广东医学院 | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1193751C (en) | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | |
| Carbo et al. | Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats | |
| Häuselmann | Nutripharmaceuticals for osteoarthritis | |
| Lu et al. | Quercetin nanoparticle ameliorates lipopolysaccharide-triggered renal inflammatory impairment by regulation of Sirt1/NF-KB pathway | |
| Kim et al. | Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect | |
| MacDonald et al. | Melatonin inhibits osteoclastogenesis and osteolytic bone metastasis: implications for osteoporosis | |
| Wang et al. | A peptide from wheat germ abolishes the senile osteoporosis by regulating OPG/RANKL/RANK/TRAF6 signaling pathway | |
| Yu et al. | Polysaccharide from Echinacea purpurea plant ameliorates oxidative stress-induced liver injury by promoting Parkin-dependent autophagy | |
| CN102397550B (en) | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis | |
| CN1947719A (en) | Application of aspirin for preventing and treating osteoporosis | |
| CN1718223A (en) | Medicine for treating osteoporosis contg. astraglus base and stanozolol | |
| CN102266415A (en) | Application of compound traditional Chinese medicine to prevention and treatment of osteoporosis disease | |
| CN1207022C (en) | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing | |
| Widyowati et al. | The effect of rusa unicolor antler deer extracts from east kalimantan in bone turnover cell models | |
| Jędrejko et al. | Effect of Cordyceps spp. and cordycepin on functions of bones and teeth and related processes: a review | |
| JP2000191544A (en) | Hepatic fibrogenetic inhibitor | |
| Shi et al. | Effect of Bushen Qudu Decoction on TGF-β1/Smads signal transduction pathway in rats with chronic renal failure | |
| Wu et al. | Studies on blocking the JAK2/STAT3 signaling pathway with elastin peptides from skipjack tuna (Katsuwonus pelamis) bulbus cordis to alleviate osteoarthritis | |
| CN108771669B (en) | Application of sulforaphane in preparation of medicine for protecting fetus blood vessel development of women drinking wine during pregnancy | |
| CN111632048B (en) | Application of dihydroartemisinin in preparation of medicine for preventing and treating hyperammonemia | |
| Nayak et al. | Dietary supplementation and medication of Vitamin C and Vitamin D in COVID-19–A hypothesis | |
| CN107970437A (en) | Cordyceps sinensis gram oncogene peptide | |
| CN107243013A (en) | A kind of composition for improving bone density and preparation method thereof | |
| CN1135892A (en) | New use of Lumbricus extract for treating female genital tract inflammation | |
| CN101032556A (en) | Novel purpose of preventing and curing osteoporosis of double-pill agent composed of moutan bark |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |